600 related articles for article (PubMed ID: 28803777)
41. Rasfonin, a novel 2-pyrone derivative, induces ras-mutated Panc-1 pancreatic tumor cell death in nude mice.
Xiao Z; Li L; Li Y; Zhou W; Cheng J; Liu F; Zheng P; Zhang Y; Che Y
Cell Death Dis; 2014 May; 5(5):e1241. PubMed ID: 24853419
[TBL] [Abstract][Full Text] [Related]
42. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.
Biffi G; Oni TE; Spielman B; Hao Y; Elyada E; Park Y; Preall J; Tuveson DA
Cancer Discov; 2019 Feb; 9(2):282-301. PubMed ID: 30366930
[TBL] [Abstract][Full Text] [Related]
43. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
[TBL] [Abstract][Full Text] [Related]
44. Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer.
Weng CC; Hsieh MJ; Wu CC; Lin YC; Shan YS; Hung WC; Chen LT; Cheng KH
Mol Cancer; 2019 May; 18(1):96. PubMed ID: 31109321
[TBL] [Abstract][Full Text] [Related]
45. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
[TBL] [Abstract][Full Text] [Related]
46. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
[TBL] [Abstract][Full Text] [Related]
47. ABCC3 is a novel target for the treatment of pancreatic cancer.
Adamska A; Ferro R; Lattanzio R; Capone E; Domenichini A; Damiani V; Chiorino G; Akkaya BG; Linton KJ; De Laurenzi V; Sala G; Falasca M
Adv Biol Regul; 2019 Aug; 73():100634. PubMed ID: 31053501
[TBL] [Abstract][Full Text] [Related]
48. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Ischenko I; Petrenko O; Hayman MJ
Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
[TBL] [Abstract][Full Text] [Related]
49. HIF-2α regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma.
Li W; Chen C; Zhao X; Ye H; Zhao Y; Fu Z; Pan W; Zheng S; Wei L; Nong T; Li Z; Chen R
J Cell Mol Med; 2017 Nov; 21(11):2896-2908. PubMed ID: 28544376
[TBL] [Abstract][Full Text] [Related]
50. Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis.
Chen L; Xu X; Wen X; Xu S; Wang L; Lu W; Jiang M; Huang J; Yang D; Wang J; Zheng M; Zhou XZ; Lu KP; Liu H
Cancer Sci; 2019 Aug; 110(8):2442-2455. PubMed ID: 31148345
[TBL] [Abstract][Full Text] [Related]
51. Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300.
Jeung YJ; Kim HG; Ahn J; Lee HJ; Lee SB; Won M; Jung CR; Im JY; Kim BK; Park SK; Son MJ; Chung KS
Biochim Biophys Acta; 2016 Nov; 1863(11):2584-2593. PubMed ID: 27452907
[TBL] [Abstract][Full Text] [Related]
52. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.
Klomp JE; Lee YS; Goodwin CM; Papke B; Klomp JA; Waters AM; Stalnecker CA; DeLiberty JM; Drizyte-Miller K; Yang R; Diehl JN; Yin HH; Pierobon M; Baldelli E; Ryan MB; Li S; Peterson J; Smith AR; Neal JT; McCormick AK; Kuo CJ; Counter CM; Petricoin EF; Cox AD; Bryant KL; Der CJ
Cell Rep; 2021 Nov; 37(9):110060. PubMed ID: 34852220
[TBL] [Abstract][Full Text] [Related]
53. Foxo3a-mediated overexpression of microRNA-622 suppresses tumor metastasis by repressing hypoxia-inducible factor-1α in ERK-responsive lung cancer.
Cheng CW; Chen PM; Hsieh YH; Weng CC; Chang CW; Yao CC; Hu LY; Wu PE; Shen CY
Oncotarget; 2015 Dec; 6(42):44222-38. PubMed ID: 26528854
[TBL] [Abstract][Full Text] [Related]
54. Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells.
Koch A; Lang SA; Wild PJ; Gantner S; Mahli A; Spanier G; Berneburg M; Müller M; Bosserhoff AK; Hellerbrand C
Oncotarget; 2015 Oct; 6(32):32748-60. PubMed ID: 26293674
[TBL] [Abstract][Full Text] [Related]
55. Peroxiredoxin 1 promotes pancreatic cancer cell invasion by modulating p38 MAPK activity.
Taniuchi K; Furihata M; Hanazaki K; Iwasaki S; Tanaka K; Shimizu T; Saito M; Saibara T
Pancreas; 2015 Mar; 44(2):331-40. PubMed ID: 25426613
[TBL] [Abstract][Full Text] [Related]
56. The KRAS-PDEδ interaction is a therapeutic target.
Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
[TBL] [Abstract][Full Text] [Related]
57. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
58. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
59. PKC Delta (PKCdelta) promotes tumoral progression of human ductal pancreatic cancer.
Mauro LV; Grossoni VC; Urtreger AJ; Yang C; Colombo LL; Morandi A; Pallotta MG; Kazanietz MG; Bal de Kier Joffé ED; Puricelli LL
Pancreas; 2010 Jan; 39(1):e31-41. PubMed ID: 19924022
[TBL] [Abstract][Full Text] [Related]
60. KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop.
Fujimura K; Wang H; Watson F; Klemke RL
Cancer Res; 2018 Mar; 78(6):1444-1456. PubMed ID: 29321164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]